Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

被引:30
作者
Bejan-Angoulvant, Theodora [1 ,2 ]
Ternant, David [1 ,3 ]
Daoued, Fadela [1 ,4 ]
Medina, Frederic [1 ,4 ]
Bernard, Louis [5 ]
Mammou, Saloua [4 ]
Paintaud, Gilles [1 ,3 ]
Mulleman, Denis [1 ,4 ]
机构
[1] Univ Tours, CNRS, Genet Immunotherapy Chem & Canc, UMR 7292, Tours, France
[2] Ctr Hosp Reg Univ CHRU Tours, Hop Bretonneau, Serv Pharmacol, Tours, France
[3] CHRU Tours, Hop Bretonneau, Lab Pharmacol Toxicol, Tours, France
[4] CHRU Tours, Hop Trousseau, Serv Rhumatol, Tours, France
[5] CHRU Tours, Hop Bretonneau, Serv Malad Infect, Tours, France
关键词
SOCIETY-FOR-RHEUMATOLOGY; ALPHA ANTAGONIST THERAPY; ANKYLOSING-SPONDYLITIS; EULAR RECOMMENDATIONS; SERIOUS INFECTIONS; CONTROLLED-TRIALS; ARTHRITIS; METAANALYSIS; ANTIBODIES; MANAGEMENT;
D O I
10.1002/art.39841
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Tumor necrosis factor inhibitors are effective in reducing inflammation in rheumatic diseases but increase the risk of infections. This study was undertaken to investigate the relationship between the trough serum concentration of infliximab (IFX) and the risk of a first infection episode. Methods. We retrospectively included all patients who started IFX treatment for an approved indication in our department. Patients were followed up based on recommended IFX infusion schedules. We studied the relationship between the occurrence of a first infection episode requiring hospitalization, anti-infection treatment, or IFX infusion deferral, and the last trough IFX concentration and mean of the last 3 trough IFX concentrations measured before the infection episode. Results. Of the 201 patients included in the analysis, 173 had spondyloarthritis (SpA). The SpA patients had a meanSD age of 46 +/- 12 years and a disease duration of 6.2 +/- 6.1 years. During a median follow-up of 1.1 year, 87 SpA patients had at least 1 infection episode. Using Cox models, we found that the probability of survival without infection was significantly higher in patients with a mean of the last 3 trough IFX concentrations lower than the median (<11.3 mg/liter) than in patients with a mean concentration greater than the median (P=0.048 by log-rank test). Glucocorticoid use and IFX concentration were significantly associated with the risk of a first infection episode in the multivariable analysis (P=0.004 for both). The risk of infection episode was significantly increased in the highest quartile of the mean of the last 3 trough IFX concentrations (>20.3 mg/liter) (hazard ratio 2.65 [95% confidence interval 1.14-6.14], P=0.023). Conclusion. Our findings indicate that a high IFX concentration is correlated with a higher risk of a first infection episode, but these findings need to be replicated in further prospective studies.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 14 条
[1]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[2]   Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis [J].
Fautrel, Bruno ;
Pham, Thao ;
Mouterde, Gael ;
Le Loet, Xavier ;
Goupille, Philippe ;
Guillemin, Francis ;
Ravaud, Philippe ;
Cantagrel, Alain ;
Dougados, Maxime ;
Puechal, Xavier ;
Sibilia, Jean ;
Soubrier, Martin ;
Mariette, Xavier ;
Combe, Bernard .
JOINT BONE SPINE, 2007, 74 (06) :627-637
[3]   Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials [J].
Fouque-Aubert, Anne ;
Jette-Paulin, Laetitia ;
Combescure, Christophe ;
Basch, Andre ;
Tebib, Jacques ;
Gossec, Laure .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (10) :1756-1761
[4]   Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 [J].
Furst, Daniel E. ;
Keystone, Edward Clark ;
So, Alexander K. ;
Braun, Juergen ;
Breedveld, Ferry C. ;
Burmester, Gerd R. ;
De Benedetti, Fabrizio ;
Doerner, Thomas ;
Emery, Paul ;
Fleischmann, Roy ;
Gibofsky, Allan ;
Kalden, J. R. ;
Kavanaugh, Arthur ;
Kirkham, Bruce ;
Mease, Philip ;
Rubbert-Roth, A. ;
Sieper, Joachim ;
Singer, Nora G. ;
Smolen, Josef S. ;
Van Riel, Piet L. C. M. ;
Weisman, Michael H. ;
Winthrop, Kevin L. .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 :2-34
[5]   The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events [J].
Leombruno, J. P. ;
Einarson, T. R. ;
Keystone, E. C. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (07) :1136-1145
[6]   Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? [J].
Mulleman, Denis ;
Ducourau, Emilie ;
Paintaud, Gilles ;
Ternant, David ;
Watier, Herve ;
Goupille, Philippe .
JOINT BONE SPINE, 2012, 79 (02) :109-112
[7]   Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis [J].
Mulleman, Denis ;
Meric, Jean-Camille ;
Paintaud, Gilles ;
Ducourau, Emilie ;
Magdelaine-Beuzelin, Charlotte ;
Valat, Jean-Pierre ;
Goupille, Philippe .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (06)
[8]   Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA [J].
Nam, J. L. ;
Winthrop, K. L. ;
van Vollenhoven, R. F. ;
Pavelka, K. ;
Valesini, G. ;
Hensor, E. M. A. ;
Worthy, G. ;
Landewe, R. ;
Smolen, J. S. ;
Emery, P. ;
Buch, M. H. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :976-986
[9]   Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis:: 2007 update [J].
Pham, Thao ;
Fautrel, Bruno ;
Dernis, Emmanuelle ;
Goupille, Philippe ;
Guillemin, Francis ;
Le Loet, Xavier ;
Ravaud, Philippe ;
Claudepierre, Pascal ;
Miceli-Richard, Corinne ;
De Bandt, Michel ;
Breban, Maxime ;
Maillefert, Jean-Francis ;
Masson, Charles ;
Saraux, Alain ;
Schaeverbeke, Thierry ;
Wendling, Daniel ;
Mariette, Xavier ;
Combe, Bernard .
JOINT BONE SPINE, 2007, 74 (06) :638-646
[10]   Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis [J].
Ramiro, Sofia ;
Gaujoux-Viala, Cecile ;
Nam, Jackie L. ;
Smolen, Josef S. ;
Buch, Maya ;
Gossec, Laure ;
van der Heijde, Desiree ;
Winthrop, Kevin ;
Landewe, Robert .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (03) :529-535